Date: 21.8.2012
In a nanotechnology two-for-one, researchers at the Johns Hopkins University Center of Cancer Nanotechnology Excellence (Hopkins CCNE) have created a polymer nanoparticle that overcomes tumor resistance to the common anticancer agent doxorubicin and that protects the heart against drug-triggered damage, a therapy-ending side effect that limits doxorubicin's effectiveness. This novel nanoparticle incorporates both doxorubicin and curcumin, a major component of the bright yellow spice turmeric.
Both in vitro and animal tests demonstrated that this formulation had striking anticancer activity in models of multiple myeloma, leukemia, and prostate and ovarian cancers. Perhaps equally important, the animals treated with the nanoparticle did not experience any cardiac toxicity or bone marrow suppression, even at cumulative doses that normally trigger cardiac toxicity by free doxorubicin or liposome-encapsulated doxorubicin, which was the first nanoparticle drug approved for use in treating cancer in humans and is widely used in treating breast cancer.
Gate2Biotech - Biotechnology Portal - All Czech Biotechnology information in one place.
ISSN 1802-2685
This website is maintained by: CREOS CZ
© 2006 - 2024 South Bohemian Agency for Support to Innovative Enterprising (JAIP)
Interesting biotechnology content:
Life Sciences Search engine - Huge database of genome, protein, gene, genome project, ..
Science - Daily Czech science news
Using AI, researchers identify a new class of antibiotic candidates that can kill a drug-resistant bacterium
Recurrent UTIs banished for up to nine years by simple oral spray